Neuropathic Pain Clinical Trial
Official title:
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
The BTP (Breakthrough pain)was defined as "a transient exacerbation of pain that occurs
either spontaneously, or in relation to a specific predictable or unpredictable trigger,
despite relatively stable and adequately controlled background pain".
The BTP is a common clinical features in patients with cancer pain (BTcP: breakthrough
cancer pain). The prevalence of BTcP is equal to 56%.
Currently, the investigators tend to recognize the idiopathic/spontaneous or accident BTcP
in the three sub-types: voluntary, non- voluntary and procedural.
The diagnosis of BTCP is not always easy because in the cancer patient is normal to observe
changes in the intensity of pain during the day, so it is necessary to differentiate slight
fluctuations from the presence of real episodes of BTCP, for which is necessary to use a
rescue treatment adjusted. In the study will be proposed the use of a diagnostic algorithm,
present in the literature, to perform the diagnosis of BTCP.
In the presence of BTCP, is important both a correct controlled background pain with major
opioids, which can reduce the number and the intensity of the painful episodes, both
implement an adjunctive therapy, called "rescue", to be administered at the time which takes
over the painful episode using, in this case, an opioid greater.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
| Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
| Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
| Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
| Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
| Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
| Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
| Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
| Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
| Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
| Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
| Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
| Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
| Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
| Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 | |
| Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 | |
| Active, not recruiting |
NCT00996983 -
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
|
Phase 2 |